Zobrazeno 1 - 10
of 53
pro vyhledávání: '"John R. Neefe"'
Autor:
Joseph T. Leimert, Julie A. Kish, Robert C. Flanigan, E. David Crawford, Anton Bueschen, Michael Wolf, John R. Neefe
Publikováno v:
Cancer. 74:916-919
Background. The response rate of metastatic renal cell cancer to cytotoxic therapy over the last 10 years has been 5.6%. Low dose continuous 5-fluorouracil (5-FU) has demonstrated efficacy in other cytotoxic refractory tumors, such as pancreas, color
Publikováno v:
Cancer Investigation. 12:399-402
Soft tissue sarcomas are generally resistant to most chemotherapeutic agents, and individuals with advanced disease have a poor prognosis. We evaluated amonafide, a new drug that has significant activity against several tumor cell lines, to determine
Publikováno v:
Cancer. 72:3191-3195
BACKGROUND Potential synergy between 5-fluorouracil (5-FU) and interferon alpha-2a (IFN-alpha-2a) has been demonstrated in the treatment of colorectal carcinoma. Continuous low-dose infusion of 5-FU may have superior response rates to bolus 5-FU in t
Autor:
Tove Thompson, Robert B. Livingston, Frederick J. Meyers, John Crowley, John R. Neefe, Stephen K. Williamson, Timothy K. O'Rourke
Publikováno v:
Cancer. 71:3509-3513
BACKGROUND Etoposide may be schedule dependent in small cell lung cancer (SCLC), and some data suggest a benefit for increased dose intensity in this disease. This study attempted to optimize dose intensity using an outpatient program that included p
Autor:
Steven M. Grunberg, Stanley P. Balcerzak, Edith A. Perez, Robert B. Livingston, Geoffrey R. Weiss, Ronald B. Natale, Thomas J. Braun, Laura F. Hutchins, Charles W. Taylor, John Crowley, Ralph W. Roach, David R. Gandara, John R. Neefe
Publikováno v:
Journal of Clinical Oncology. 11:873-878
PURPOSE To test the concept that cisplatin dose-intensity is important in the treatment of non-small-cell lung cancer (NSCLC), the Southwest Oncology Group (SWOG) performed a randomized trial comparing standard-dose cisplatin (SDCP) 50 mg/m2 days 1 a
Autor:
Brian J. Wiatrak, Richard J.H. Smith, Craig S. Derkay, James E. Arnold, John R. Neefe, Jo Anne H. Van Burik, Bruce Berger, John E. McClay
Publikováno v:
The Annals of otology, rhinology, and laryngology. 114(9)
Objectives: We sought to evaluate the effectiveness of HspE7, a recombinant fusion protein of Hsp65 from Mycobacterium bovis BCG and E7 protein from human papillomavirus 16, to improve the clinical course of pediatric patients with recurrent respirat
Autor:
P. Y. Liu, John R. Neefe, David S. Alberts, Geoffrey R. Weiss, Thomas D. Brown, Laura F. Hutchins, Janet O'Sullivan
Publikováno v:
Gynecologic oncology. 45(3)
Patients with measurable metastatic or recurrent squamous carcinoma of the uterine cervix who had failed prior surgery or radiation therapy were enrolled on this randomized phase II study. Twenty-seven eligible patients were assigned to receive didem
Autor:
John S. Macdonald, T. J. O'Rourke, Thomas R. Fleming, Phyllis J. Goodman, Ellen R. Gaynor, Thomas D. Brown, Sarah A. Taylor, John R. Neefe
Publikováno v:
Journal of immunotherapy : official journal of the Society for Biological Therapy. 10(5)
Fifty evaluable patients with advanced colorectal cancer, but without prior chemotherapy or immunotherapy, were randomized to one of two schedules of recombinant gamma-interferon (rGIFN). Twenty-four evaluable patients received rGIFN as a 2-h intrave
Autor:
John R. Neefe, Jerome Groopman, Sydney Salmon, Lydia Evans, Frank L. Meyskens, Marilyn Campion, Sewa S. Legha, Ari Markowitz
Publikováno v:
Neefe, JR; Legha, SS; Markowitz, A; Salmon, S; Meyskens, F; Groopman, J; et al.(1990). Phase II Study of Recombinant α-Interferon in Malignant Melanoma. American Journal of Clinical Oncology, 13(6), 472-476. doi: 10.1097/00000421-199012000-00004. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/6863g4c0
Ninety-seven evaluable patients with measurable, advanced, malignant melanoma were treated with recombinant alpha interferon in a cooperative phase II efficacy trial, whose primary objective was to estimate the response rate. Interferon (rIFN alpha-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d47e050cdc712813a808d6318119784
http://www.escholarship.org/uc/item/6863g4c0
http://www.escholarship.org/uc/item/6863g4c0
Autor:
Frederick P. Smith, Paul V. Woolley, Richard M. Goldberg, S Korec, Philip S. Schein, John R. Neefe, T M Phillips
Publikováno v:
Journal of Clinical Oncology. 4:210-215
Plasma perfusion over filters containing staphylococcal protein A (SPA) was used to treat 11 patients with adenocarcinoma who developed a hemolytic uremic syndrome. Immunoperfusion resulted in complete clearance of pretreatment elevated levels of cir